PhD (Biochemistry)

Additional Qualification: National Postdoctoral Fellowship

• Cancer Biology
• Immunoproteomics
• Molecular Biology

1. Society of Biological Chemists (India), Life Membership No. 3021, 2013
2. Training program on ‘Transgenic Animal Technology: Basics and Methods’, from Ministry of Human Resource Development Govt. of India, in School of Life Sciences, University of Hyderabad.
3. Training for ‘Molecular Biology & Cloning’ and ‘Protein Expression, Purification and Analysis’. GeNext Genomics Pvt. Ltd. Nagpur
4. Interdisciplinary Workshop on ‘Research Methodologies’, Dr. Ambedkar Institute of Management Studies and Research, Nagpur
5. Training on ‘Statistical Methods’ by RTM Nagpur University in Department of Statistics, Hislop Collage, Nagpur
6. Workshop on ‘Patents and Related Issues’, by Technology Park, Patent Cell, Nagpur
7. Workshop cum training program on ‘Rattus Species: In Research and Education’, by Continuing Technical Skill Development Program, Department of Biochemistry, RTM Nagpur University, Nagpur
8. Workshop cum training program on ‘Bioinformatics’ in collaboration of Sai Bioinfosys and Department of Biochemistry, RTM Nagpur University, Nagpur.

1. Ahmad S, Butle A, Karn A, Sunder R, Mishra R, Bawaskar B, et al., CDKN1B inactivation impacts ER signaling and drives resistance to endocrine therapy in breast cancer. Nature- Br J Cancer. 2026 Apr 22. doi: 10.1038/s41416-026-03388-z. Epub ahead of print. PMID: 42020778 IF: 6.80
2. Dharavath B, Butle A, Chaudhary A, Pal A, Desai S, Chowdhury A, et al., Recurrent UBE3C-LRP5 translocations in head and neck cancer with therapeutic implications. Nature- Precision Oncology,. 2024 Mar 4;8(1):63. doi: 10.1038/s41698-024-00555-4. PMID: 38438481; PMCID: PMC10912599. IF: 10.09
3. Dharavath B, Butle A, Pal A, Desai S, Upadhyay P, Rane Aet al.,  Role of miR-944/MMP10/AXL- axis in lymph node metastasis in tongue cancer. Nature- Commun Biol. 2023 Jan 17;6(1):57. doi: 10.1038/s42003-023-04437-6. PMID: 36650344; PMCID: PMC9845355. IF: 6.54
4. Butle A#, Joshi A#, Hait S, Mishra R, Trivedi V, Thorat R, et al., Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation. Transl Oncol. 2022 Aug;22:101461. doi: 10.1016/j.tranon.2022.101461. PMID: 35653897; PMCID: PMC9156817. IF: 4.80
5. Butle A#, Joshi A#, Noronha V, Prabhash K, Dutt A. Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs. Transl Oncol. 2021 Aug;14(8):101111. doi: 10.1016/j.tranon.2021.101111. Epub 2021 May 13. PMID: 33993094; PMCID: PMC8236545. IF: 4.80

1. Prime Minister-Early Carrier Research Grant, ANRF- Department of Science and Technology, Govt of India
2. National Post Doctoral Fellowship, SERB-Department of Science and Technology, Govt of India, New-Delhi
3. Scientist-E (Ad-hoc), bestowed by Director ACTREC, Tata Memorial Center, Navi Mumbai
4. Institutional Post Doctoral Fellowship, ACTREC, Tata Memorial Center, Navi Mumbai
5. First Rank (Abstract Presentation): An orthotopic mice model for lung cancer closely recapitulates the clinical disease in NOD-SCID mice. Annual Conference of Oncology Forum. OFCON 2020
6. First Rank (Abstract presentation): Isolation of Immunomodulatory Protein from the Seeds of Zizyphus mauritiana. National Conference on Recent Trends in Life Science Material Sciences and Home Sciences, 04 Oct 2015, at Hotel Center point, by SMV Nagpur.

RESEARCH PROJECTS   (PRINCIPAL INVESTIGATOR)

1. Characterization of novel α-D - galactose specific immunostimulatory and antiallergic heterotrimeric protein with its anticancer activity. Funded by Intramural Research Grant AIIMS, Nagpur  (Oct.2025 to Sept 2027)
2. Combinatorial Tyrosine Kinase Inhibitors (TKIs) as a Promising Therapeutic Strategy for Cervical Cancer in Indian Patients. Funded by ANRF- ECRG, Govt. if India (May 2025 to Jan.2028)
3. Characterization of therapeutically relevant alterations in cervical cancer using orthotopic mice models. Two years project, Funded by SERB-DST Govt. if India (May 2022 to Jan.2024)

PUBLICATIONS

1. Ahmad S, Butle A, Karn A, Sunder R, Mishra R, Bawaskar B, et al., CDKN1B inactivation impacts ER signaling and drives resistance to endocrine therapy in breast cancer. Nature- Br J Cancer. 2026 Apr 22. doi: 10.1038/s41416-026-03388-z. Epub ahead of print. PMID: 42020778 IF: 6.80
2. Dharavath B, Butle A, Chaudhary A, Pal A, Desai S, Chowdhury A, Thorat R, Upadhyay P, Nair S, Dutt A. Recurrent UBE3C-LRP5 translocations in head and neck cancer with therapeutic implications. Nature, Precision Oncology,. 2024 Mar 4;8(1):63. doi: 10.1038/s41698-024-00555-4. PMID: 38438481; PMCID: PMC10912599. IF: 10.09
3. Butle A, Rekhi B, Dave V, Dharavath B, Khetle S, Redhu AK, et al. Immunohistochemical expression of H3.3 G34W in 100 giant cell tumors of bone and its diagnostic mimics, including its value in resolving uncommon diagnostic scenarios: A single institutional study at a tertiary cancer referral center, India. Indian J Pathol Microbiol. 2024 Feb 12. doi:10.4103/ijpm.ijpm_886_23. Epub ahead of print. PMID: 38391356. IF: 2.13
4. Trivedi V, Noronha V, Butle A, Mishra R, Bal M, Mittal N, et al. Association of Cutibacterium acnes with human thyroid cancer. Front Endocrinol (Lausanne). 2023;14:1152514. oi:10.3389/fendo.2023.1152514. IF: 6.05
5. Rekhi B, Dave V, Butle A, Dutt A. Utility of immunohistochemical expression of H3.3K36M and DOG1 in the diagnosis of chondroblastomas: An experience from a tertiary cancer referral center. Ann Diagn Pathol. 2023 Oct;66:152174. doi: 10.1016/j.anndiagpath.2023.152174. Epub 2023 Jun 21. PMID: 37356274. IF: 2.13
6. Dharavath B, Butle A, Pal A, Desai S, Upadhyay Pet al.,. Role of miR-944/MMP10/AXL- axis in lymph node metastasis in tongue cancer. Nature- Commun Biol. 2023 Jan 17;6(1):57. doi: 10.1038/s42003-023-04437-6. PMID: 36650344; PMCID: PMC9845355. IF: 6.54
7. Butle A, Joshi A, Noronha V, Prabhash K, Dutt A. Weekly osimertinib dosing to prevent EGFR mutant tumor cells destined to home mouse lungs. J Clin Oncol. 2021;39(15_suppl):e20504. doi:10.1200/JCO.2021.39.15_suppl.e20504. American Society of Clinical Oncology IF: 50.79
8. Butle A#, Joshi A#, Hait S, Mishra R, Trivedi V, Thorat R, et al., Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation. Transl Oncol. 2022 Aug;22:101461. doi: 10.1016/j.tranon.2022.101461. PMID: 35653897; PMCID: PMC9156817. IF: 4.80
9. Desai S, Dharavath B, Manavalan S, Rane A, Redhu AK, Sunder R, Butle A et al.,  Fusobacterium nucleatum is associated with inflammation and poor survival in early-stage HPV-negative tongue cancer. NAR Cancer. 2022 Mar 4;4(1):zcac006. doi: 10.1093/narcan/zcac006. PMID: 35252868; PMCID: PMC8894079. IF: 5.1
10. Butle A#, Joshi A#, Noronha V, Prabhash K, Dutt A. Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs. Transl Oncol. 2021 Aug;14(8):101111. doi: 10.1016/j.tranon.2021.101111. Epub 2021 May 13. PMID: 33993094; PMCID: PMC8236545. IF: 4.80
11. Butle AB, Talmale SA, Jadhao VV, Patil MB, Lambat TL. Immunostimulatory and anti-allergic potential of novel heterotrimeric lectin from seeds of Zizyphus mauritiana Lam. Int J Biol Macromol. 2021 Feb 28;171:389-397. doi: 10.1016/j.ijbiomac.2021.01.027. Epub 2021 Jan 9. PMID: 33428960. IF: 8.5
12. Lambat T, Deo S, Butle A. Plasma marker based hepatoprotective evaluation of some novel synthesized benzofluorenone analogues: A medicinal chemistry approach, Karbala Int J Mod Sci. 2017 1;3: 39 – 45. ISSN 2405-609X; https://doi.org/10.1016/j.kijoms.2017.02.002. IF: 1.53

INVITED PRESENTATIONS

1. Guest Talk, Sindhu Mahavidyalaya, Nagpur, India 21st March 2025, Topic: Revolutionizing Lung Cancer Treatment: Third-Generation TKIs as the New Standard of Care
2. Guest Lecture, Guru Nanak Mahavidyalaya, Chandrapur, 23rd December 2024, Topic: Role of MiR-944/MMP10/AXL-axis in lymph node metastasis in tongue cancer.
3. Expert Talk, Central University Bilaspur, Department of Biotechnology, on 13th December, Topic: Osimertinib for Lung Cancer: A Preclinical Data
4. Faculty Speaker in 5th Masterclass in Lung Cancer held on 22nd, 23rd & 24th July 2022 at Hotel Courtyard by Marriott, Mumbai. Topic: Weekly Osimertinib In Lung Cancer – Pre-Clinical Data.

PROFESSIONAL CO-CURRICULAR ACTIVITIES

1. Sept. 2024: Workshop Coordinator Digital PCR in health and Research, Department of Biochemistry, AIIMS, Nagpur
2. Mar. 2019: Demonstrator for protein purification protocols in workshop entitled ‘Proteomics and Zoonoses Research’, Department of Veterinary Public Health, Nagpur Veterinary Collage, Nagpur
3. Mar. 2017: Guest Talk for Workshop cum Training Program on Biochemical Research Techniques on topic ‘Methodologies in Statistical Analysis’, in Department of Biochemistry, RTM Nagpur University, Nagpur.
4. Mar. 2017: Demonstrator and Speaker for Workshop cum Training Program on Biochemical Research Techniques on topic ‘Protein Electrophoresis’, in Department of Biochemistry, RTM Nagpur University, Nagpur
5. Mar. 2017: Demonstrator cum Resource Person for Workshop cum Training Program on Biochemical Research Techniques ‘Free Radicals and Scavengers in Health and Disease’, in Department of Biochemistry, RTM Nagpur University, Nagpur.
6. Feb. 2015: Demonstrator and Speaker for Rabbit handling and sample collection in workshop cum training program on ‘Animals and Alternatives in Toxicity Testing’, in Department of Biochemistry, RTM Nagpur University, Nagpur.
7. Feb. 2014: Demonstrator for Rabbit handling and sample collection in workshop cum training program on ‘Research Skills: Animal Use, Statistical Analysis & Soft Skill Development’, in Department of Biochemistry, RTM Nagpur University, Nagpur.

NEWS MEDIA REPORTS

2024: Indian team uses repurposed drug to treat oral cancer subtype. THE HINDU, March 16, 2024 09:24 pm | Updated March 18, 2024 06:06 pm IST. https://www.thehindu.com/sci-tech/science/indian-team-uses-repurposed-drug-to-treat-oral-cancer-subtype/article67954811.ece (The Hindu)

UBE3C-LRP5 is a novel oncogenic driver and potential therapeutic target in head and neck cancer. SPRINGERNATURE Research Communities. Mar 11, 2024. https://communities.springernature.com/posts/ube3c-lrp5-is-a-novel-oncogenic-driver-and-potential-therapeutic-target-in-head-and-neck-cancer?utm_source=user_mailer&utm_medium=email&utm_campaign=send_content_share_for_existing_user

2023: Tata Memorial develops novel biomarker for tongue cancer spread to spare 70% patients from neck surgery. https://indianexpress.com/article/health-wellness/tata-memorial-develops-novel-biomarker-for-tongue-cancer-spread-to-spare-70-patients-from-neck-surgery-8424234/ (The Indian Express)

2022: New study recommends next-generation sequencing for extending lung cancer treatment to more patients. https://indianexpress.com/article/cities/pune/new-study-next-generation-sequencing-lung-cancer-treatment-patients-7959103/ (The Indian Express)